The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Reduced Serum Uric Acid Levels May Protect Against Renal Function Decline

Reduced Serum Uric Acid Levels May Protect Against Renal Function Decline

April 2, 2018 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Previous studies have found that patients with gout who have lower serum uric acid (SUA) levels are less likely to experience a cardiometabolic event than those with higher SUA levels. New research suggests that these patients also appear to have a reduced risk of renal function decline. This reduced risk has potential clinical implications, because many patients with gout eventually develop chronic kidney disease Stage 3 or higher. Although Rishi J. Desai, PhD, instructor of medicine at Brigham and Women’s Hospital & Harvard Medical School in Boston, and colleagues found an association between SUA and renal function decline, they surprisingly found no association between reduction in SUA and diabetes mellitus or cardiovascular disease (CVD). The authors published their results online Feb. 28 in PLoS ONE.1

You Might Also Like
  • Canakinumab Reduces Risk for Gout Flares, But Not Serum Uric Acid Levels
  • Effect of Diet & Sodium Intake on Serum Uric Acid
  • Serum Uric Acid May Be Link between Sleep Apnea and Cardiovascular Disease
Also By This Author
  • Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease

The large observational study consisted of 26,341 patients with gout who had SUA measurements of 6.8 mg/dL or higher. The median baseline SUA in the cohort was 8.6 mg/dL. The average age of the patients was 62 years and 75% were men. The investigators did not include patient race, weight, blood pressure or smoking intensity in their analysis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The cohort included 16,334 non-diabetic patients and 21,491 patients with no recorded CVD, congestive heart failure or revascularization procedures. Data from these individuals were used to analyze incident diabetes mellitus risk and incident CVD risk. The cohort also included 21,182 patients with recorded serum creatinine results once at baseline and at least once in the follow-up period. Data from these individuals were used to analyze renal function decline.

The average follow-up in the study was 2.8 years for the diabetes mellitus and CVD subcohorts and 2.6 years in the renal function decline sub-cohort. Over the course of this follow-up, approximately 60% of patients were treated with a urate-lowering agent. During this time, the investigators identified 749 diabetes mellitus events, 470 CVD events and 2,373 renal function decline events. The overall incidence rate for diabetes mellitus was 1.63/100 person-years and for CVD was 0.77/100 person-years. The overall incidence rate for renal function decline was 4.32/100 person-years.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Using these data, the investigators calculated an adjusted hazard ratio (HR) for a 3 mg/dL reduction in SUA. They chose this number because, on average, it corresponded to achieving the target level of less than 6 mg/dL. The adjusted HR was 1.04 (0.92–1.17) for diabetes mellitus, 1.07 (0.89–1.29) for CVD and 0.85 (0.78–0.92) for renal function decline. When the researchers performed a sensitivity analysis among patients not on angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers at baseline, they found the association between 3 mg/dL reduction in SUA and renal function decline was consistent with the primary analysis (adjusted HR of 0.82, 0.72–0.94). When the investigators performed a secondary analysis during which cumulative changes in SUA during follow-up were modeled as restricted cubic splines, they found that reductions in SUA continued to be associated with a significant decrease in risk for renal function decline (HR for reduction by 3 mg/dL was 0.83, 0.78–0.89).

Pages: 1 2 | Single Page

Filed Under: Conditions, Crystal Arthritis Tagged With: chronic kidney disease, Gout, kidney, Uric acid

You Might Also Like:
  • Canakinumab Reduces Risk for Gout Flares, But Not Serum Uric Acid Levels
  • Effect of Diet & Sodium Intake on Serum Uric Acid
  • Serum Uric Acid May Be Link between Sleep Apnea and Cardiovascular Disease
  • Antiplatelet Therapy May Protect Renal Function in Some Lupus Patients

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)